Investigational drug · Phase 2
AP1189
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Rheumatoid Arthritis (RA), Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy, Severe Proteinuria Due to Idiopathic Membranous Nephropathy.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
6
Any phase or sponsor naming "AP1189"
First trial start
2020
Aug 31, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AP1189", any sponsor or status.
Conditions studied
As listed on its trial records.
- Rheumatoid Arthritis (RA)
- Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy
- Severe Proteinuria Due to Idiopathic Membranous Nephropathy
- Respiratory Viral Infection
Approved drugs for the same conditions: Rheumatoid arthritis · Immunology and inflammation · Infectious disease and vaccines · Rare and genetic disease · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "AP1189" as an intervention, largest first.
- A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid ArthritisPivotal-lookingRecruiting
SynAct Pharma ApsIndustry
NCT06671054 · 240 participants (planned) · Start Oct 1, 2024 · Primary completion Dec 2025
Drug: AP1189, 40 mg; AP1189, 70 mg and 2 more · For: Rheumatoid Arthritis (RA)
Sites: Cutler Bay, Florida; Miami, Florida; Duncansville, Pennsylvania · 11 sites in all
- A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD TreatmentPivotal-lookingCompleted
SynAct Pharma ApsIndustry
NCT05516979 · 127 participants · Start Sep 26, 2022 · Primary completion Jul 20, 2023
Drug: 100 mg AP1189; Placebo · For: Rheumatoid Arthritis
Sites: Chisinau, Moldova
- A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to MethotrexatePivotal-lookingCompleted
SynAct Pharma ApsIndustry
NCT05604885 · 125 participants · Start Nov 30, 2022 · Primary completion Aug 28, 2023
Drug: AP1189, 60 mg; AP1189, 80 mg and 2 more · For: Rheumatoid Arthritis
Sites: Chisinau, Moldova
- A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint DiseasePivotal-lookingCompleted
SynAct Pharma ApsIndustry
NCT04004429 · 105 participants · Start Aug 26, 2019 · Primary completion Nov 16, 2021
Drug: 50 mg AP1189; AP1189 and 1 more · For: Rheumatoid Arthritis
Sites: Aarhus, Denmark; Oslo, Norway
SynAct Pharma ApsIndustry
NCT07633288 · 96 participants (planned) · Start May 1, 2026 · Primary completion Aug 1, 2027
Drug: AP1189, 100 mg; Placebo · For: Respiratory Viral Infection
Sites: Mostar, Bosnia and Herzegovina; Banja Luka, Bosnia and Herzegovina; Sarajevo, Bosnia and Herzegovina · 11 sites in all
SynAct Pharma ApsIndustry
NCT04456816 · 23 participants (planned) · Start Aug 31, 2020 · Primary completion Jun 30, 2026
Drug: 100 mg AP1189; Placebo · For: Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy; Severe Proteinuria Due to Idiopathic Membranous Nephropathy
Sites: Aarhus, Denmark
Newest research
PubMed records naming it or its code names, newest first.
- Resolution of inflammation: A novel therapeutic paradigm for rheumatoid arthritis and its comorbidities.
Yazdi RF, Tan SI, Bu W, et al. · Pharmacol Res 2026
- Pro-resolving lipid mediators and therapeutic innovations in resolution of inflammation.
Peh HY, Chen J · Pharmacol Ther 2025
- Effects of a pro-resolving drug in COVID-19: preclinical studies to a randomized, placebo-controlled, phase Ib/IIa trial in hospitalized patients.
Almeida PRJ, Periard AM, Tana FL, et al. · Br J Pharmacol 2024
- Biased agonism as a novel strategy to harness the proresolving properties of melanocortin receptors without eliciting melanogenic effects.
Montero-Melendez T, Gobbetti T, Cooray SN, et al. · J Immunol 2015
Also in development for Rheumatoid Arthritis (RA)
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
Beijing VDJBio Co., LTD. · Anti IL-6R, Idiopathic Multicentric Castleman's Disease, Castleman's Disease, Multicentric
- proposed biosimilar to etanerceptMB04Phase 31 trial
mAbxience Research S.L. · Rheumatoid Arthritis (RA)
- QLS12010Phase 23 trials
Qilu Pharmaceutical Co., Ltd. · Adults With Moderate-to-severe Hidradenitis Suppurativa, Moderate-to-severe Atopic Dermatitis, Rheumatoid Arthritis (RA)
- JAB-8263Phase 22 trials
Jacobio Pharmaceuticals Co., Ltd. · Rheumatoid Arthritis (RA), NSCLC, SCLC
- TollB-001Phase 22 trials
Toll Biotech Co. Ltd. (Beijing) · Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc)
- FT839Phase 21 trial
Fate Therapeutics · ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA)
- QEL-005Phase 21 trial
Quell Therapeutics Limited · Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.